NCT05490030View on ClinicalTrials.gov

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 6, 2025

Primary Completion Date

June 26, 2025

Study Completion Date

June 26, 2025

Conditions
Hepatic Impairment
Interventions
DRUG

TNO155

Single oral dose of TNO155 on Day 1

Sponsors
All Listed Sponsors
collaborator

Pharmaceutical Research Associates

OTHER

lead

Novartis Pharmaceuticals

INDUSTRY